Compare SUI & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SUI | PODD |
|---|---|---|
| Founded | 1975 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.9B | 17.0B |
| IPO Year | 1996 | 2007 |
| Metric | SUI | PODD |
|---|---|---|
| Price | $130.15 | $199.96 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 20 |
| Target Price | $140.57 | ★ $347.55 |
| AVG Volume (30 Days) | 571.8K | ★ 796.4K |
| Earning Date | 04-27-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.43% | N/A |
| EPS Growth | ★ 1426.76 | N/A |
| EPS | ★ 10.84 | 3.48 |
| Revenue | $2,306,100,000.00 | ★ $2,708,100,000.00 |
| Revenue This Year | $5.24 | $24.59 |
| Revenue Next Year | $5.08 | $19.18 |
| P/E Ratio | ★ $12.02 | $58.48 |
| Revenue Growth | N/A | ★ 30.73 |
| 52 Week Low | $115.53 | $194.61 |
| 52 Week High | $137.85 | $354.88 |
| Indicator | SUI | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 52.37 | 32.55 |
| Support Level | $124.34 | $194.61 |
| Resistance Level | $137.72 | $299.75 |
| Average True Range (ATR) | 2.18 | 5.68 |
| MACD | 0.33 | 1.15 |
| Stochastic Oscillator | 84.90 | 29.63 |
Sun Communities is a residential REIT that focuses on owning manufactured housing and residential vehicle communities. The company currently owns a portfolio of 501 properties, which includes 337 manufactured housing communities and 164 residential vehicle communities. Sun targets owning properties that are desirable as second homes or vacation properties with nearly 50% of the portfolio located in either Florida or Michigan near major bodies of water.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.